Salute e Benessere

Grünenthal acquires US-company Valinor Pharma and becomes global owner of…

"As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio", says Gabriel Baertschi, CEO, Grünenthal. "The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal." "As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio", saysGabriel Baertschi, CEO…
PR Newswire
22/07/2024

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to…

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across EuropeLaunch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology 1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently...
Nasdaq GlobeNewswire
22/07/2024

Biosimilar Market to Surpass $102.68 Billion by 2034 with 8.9% Annual Growth…

Global demand for biosimilars is rising as healthcare systems seek cost-effective alternatives to expensive biologic medications. These highly similar biologics are gaining popularity worldwide due to their equivalent efficacy, safety, and affordability. The anticipated growth in the biosimilar market in the coming years will be driven by the expiration of patents on blockbuster biologics and the imperative to reduce healthcare expenditures. Global demand for biosimilars is rising as…
PR Newswire
22/07/2024

Buyback of Class B shares in Essity during week 29, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
22/07/2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for…

“ZW191 is a differentiated product candidate in our pipeline that reflects the strength of our approach in developing best-in-class antibody-drug conjugates,” said Paul Moore, Chief Scientific Officer of Zymeworks. “Developed to target FR⍺, which is expressed in several types of difficult-to-treat cancers, ZW191 incorporates a novel antibody and drug-linker that provide a unique combination of antibody-linker stability and payload potency, together with strong bystander activity, which...
Nasdaq GlobeNewswire
22/07/2024

JPA Health Expands Global Presence with Acquisition of Award-Winning akt health…

Founded in 2018 by Anna Radnavale, Katy Foy and Tim Cockroft, akt health offers a bespoke service to healthcare clients, motivated by a central mission to make the world a healthier place while improving and protecting lives. The team has received global recognition for their work across Diversity & Inclusion Communications, Healthcare PR, Digital and Multichannel Communications. Founded in 2018 by Anna Radnavale,Katy FoyandTim Cockroft, akt health offers a bespoke service to healthcare...
PR Newswire
22/07/2024

SIFI Receives COMP Positive Opinion on Orphan Drug Designation for Polihexanide…

Polihexanide received an ODD in fungal keratitis from the US Food and Drug Administration (FDA) in February 2022. Polihexanide received an ODD in fungal keratitis from the US Food and Drug Administration (FDA) inFebruary 2022. Fungal keratitis, a severe infection of the cornea caused by fungi such as Fusarium, Aspergillus, and Candida species, is a significant cause of ocular morbidity and unilateral blindness worldwide 1. Although rare, this condition can lead to substantial vision loss...
PR Newswire
22/07/2024

Addex's Partner Discontinues ADX71149 development in Epilepsy

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy...
Nasdaq GlobeNewswire
22/07/2024

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support…

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICsIXCHIQ®isalreadyapproved for use in adults 18 years of age and older in the U.S., Canada and EuropeOslo, Norway, and Saint-Herblain, France, July...
Nasdaq GlobeNewswire
22/07/2024

Transparency Notifications from Shareholders

Transparency Notifications from ShareholdersPRESS RELEASE REGULATED INFORMATION 19 July 2024, 06:30 pm CESTGhent, Belgium – 19 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the shareholder listed below, notifying the number of voting rights attached to the shares…
Nasdaq GlobeNewswire
19/07/2024

Information on the Total Number of Voting Rights (Denominator) following…

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion...
Nasdaq GlobeNewswire
19/07/2024

BioSenic S.A. : Transparency notification received from Mr François Rieger

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 19, 2024, 6pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Mr François Rieger. The details of the transparency notification are set out below and the full text of...
Nasdaq GlobeNewswire
19/07/2024

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 19, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), and other diseases with significant unmet medical needs, today announced the half-year...
Nasdaq GlobeNewswire
19/07/2024

Cell Therapy Market to Attain a USD 190.91 Billion Valuation in 2031, Rising…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/cell-therapy-market Cell Therapy Market Overview: Segments covered in Cell Therapy Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/cell-therapy-market High Demand for Novel Cancer Treatments to Help Oncology Segment Maintain Prominence Cases of cancer are increasing rapidly on a global level and...
PR Newswire
19/07/2024

Cancer Gene Therapy Market to Attain a USD 12.63 Billion by 2031; Advancements…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/cancer-gene-therapy-market Cancer Gene Therapy Market Overview: Segments covered in Cancer Gene Therapy Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/cancer-gene-therapy-market Gene Therapies for Breast Cancer Treatment are Slated to be Highly Popular Going Forward The incidence of breast...
PR Newswire
19/07/2024

Immunotherapy Drugs Market worth $580.6 billion by 2029 driven by Technological…

Browse in-depth TOC on "Immunotherapy Drugs Market" Browse in-depth TOC on "Immunotherapy Drugs Market" 341 - Tables 53 - Figures 348 - Pages MERCK & CO., INC. (US): Innovator in Immunotherapy Merck & Co., Inc. stands out as a leader in the immunotherapy sector, showcasing a robust pipeline of advanced immunotherapeutic drugs through the utilization of cutting-edge biotechnologies. The company's expertise spans therapeutic areas including oncology, immunology,...
PR Newswire
19/07/2024

Indwelling Catheters Market to reach US$ 1.9 Billion by 2031: Rising Awareness…

Indwelling catheters offer a less invasive alternative to traditional methods for managing urinary issues, driving their adoption. Growth in healthcare expenditure, particularly in developing regions, supports the adoption of advanced medical devices like indwelling catheters. Indwelling catheters offer a less invasive alternative to traditional methods for managing urinary issues, driving their adoption. Growth in healthcare expenditure, particularly in developing regions, supports the...
PR Newswire
19/07/2024

New Paper Underscores Inflammation's Role in Atherosclerosis

The paper has four main sections: The paper has four main sections: Assessment & Treatment of Inflammation in Atherosclerosis is authored by four international experts: READ WHITE PAPER: Assessment & Treatment of Inflammation in Atherosclerosis STATEMENT FROMPETER LIBBY, MD, PRESIDENT, INTERNATIONAL ATHEROSCLEROSIS SOCIETY AND CHAIR OF THE WHITE PAPER EXPERT PANEL:"Atherosclerosis is a primary cause of cardiovascular disease, the leading cause of death worldwide...
PR Newswire
19/07/2024

I Love Fruit & Veg from Europe: the beneficial properties of berries

Berries are an obvious choice because they contain plenty of water and fibre, vitamins, mineral salts and antioxidants. They also contain polyphenols, which have a fat-burning effect. Whether eaten fresh, in preserves or juices, they make a perfect snack for those on a diet: berries are low in calories but highly nutritious and they can give a sense of fullness; they can also help to control cholesterol. Furthermore, they are easily absorbed and have diuretic, purifying and laxative properties -…
PR Newswire
19/07/2024

Inspire Medical Systems, Inc. Announces CE Mark Certification under the European…

/745) for Inspire therapy. “Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010,” said Tim Herbert, Chairman and President of Inspire. “The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries.”“In 2017...
Nasdaq GlobeNewswire
19/07/2024

Inspire Medical Systems, Inc. Announces CE Mark Certification of Full-Body MRI…

“Expanding compatible use to include full-body MRI is a significant milestone in our effort to bring Inspire to more obstructive sleep apnea patients who struggle with CPAP. Providing the full range of scan options enables us to better help all current and future patients with their imaging needs,” said Tim Herbert, Chairman and CEO of Inspire. “This full-body MRI compatibility has been an important benefit for patients in the United States for the past two years, and this new approval will...
Nasdaq GlobeNewswire
19/07/2024

Nicox announces attendance at upcoming conferences

Press ReleaseNicox announces attendance at upcoming conferences July 19 th, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its attendance at several upcoming international conferences: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 (Virtual)H.C. Wainwright 26th Annual Global Investment Conference, September...
Nasdaq GlobeNewswire
19/07/2024

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative…

Ms. Stella SHI, CEO and Founder of Rona Therapeutics, commented, "We are thrilled to welcome LongRiver Investments and our other new investors as we progress more best-in-class and first-in-class siRNA programs into global development and catalyzing potential business development opportunities. Rona Therapeutics remains committed to pushing boundaries of RNA medicine in metabolic, obesity, renal and neuro degenerative diseases with Rona's proprietary RNA platform." Ms. Stella SHI, CEO…
PR Newswire
19/07/2024

Casino Group Communication

Casino Group Communication Paris, 18 July 2024Casino Group confirms that Casino Guichard Perrachon has been the subject of a preliminary investigation by the National Financial Prosecutor's Office (PNF: Parquet National Financier) into facts likely to be qualified as price manipulation and private corruption dating back to 2018 and 2019, at the end of which an exchange phase with the PNF has been initiated. At this stage of the proceedings, Casino has not been referred to a criminal court...
Nasdaq GlobeNewswire
18/07/2024
Altri  Comunicati